Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.37 |
| ▸ | PDK2 | Q15119 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | APEX1 | P27695 | 1/20 | 0.32 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | METAP2 | P50579 | 2/20 | 0.31 |
| ▸ | RARB | P10826 | 1/20 | 0.31 |
| ▸ | RARG | P13631 | 1/20 | 0.31 |
| ▸ | RXRA | P19793 | 1/20 | 0.31 |
| ▸ | METAP1 | P53582 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16109637 | 0.89 | THRB (0.34) | THRBTDP1AKR1C1PDK2HDAC4 | |
| SCHEMBL28438786 | 0.74 | AKR1C1 (0.38) | AKR1C1APEX1NPSR1RXRAMAPK1 | |
| SCHEMBL9297425 | 0.71 | AKR1C1 (0.38) | THRBTDP1AKR1C1KMT2ATSHR | |
| SCHEMBL9682817 | 0.71 | AKR1C1 (0.38) | THRBTDP1AKR1C1KMT2ATSHR | |
| SCHEMBL15657621 | 0.68 | SLC6A2 (0.31) | — | |
| SCHEMBL13447808 | 0.68 | TRPA1 (0.32) | TDP1 | |
| SCHEMBL11614553 | 0.66 | AKR1C1 (0.41) | AKR1C1 | |
| SCHEMBL9693321 | 0.65 | AKR1C1 (0.37) | THRBTDP1AKR1C1KMT2AHDAC4 | |
| SCHEMBL9296436 | 0.65 | LMNA (0.43) | TDP1 | |
| SCHEMBL9296444 | 0.65 | LMNA (0.43) | TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9896402-B2 | Method for preventing decrease in optical purity | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2018-02-20 | — | — | US | disclosed |
| US-20140296582-A1 | METHOD FOR PREVENTING DECREASE IN OPTICAL PURITY | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2014-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140296582-A1 | METHOD FOR PREVENTING DECREASE IN OPTICAL PURITY | QDPR, NOX4, NOX5 | THRB 4836/4885TDP1 3730/4885AKR1C1 2057/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.